00:56 , Jul 31, 2019 |  BC Extra  |  Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
20:32 , Jul 29, 2019 |  BC Extra  |  Company News

With Mylan deal, Pfizer seeks faster growth via innovation focus

Pfizer's decision to spin out its off-patent unit and merge it with Mylan will give investors greater optionality, as management expects the remaining pharma to be a smaller but faster-growing company focused more narrowly on...
15:40 , Jul 1, 2019 |  BC Extra  |  Company News

Long wait cost Pfizer until BEACON data clinched Array deal

By waiting for a crucial clinical readout that arrived in May 2019, Pfizer watched Array's stock price climb for two years, eventually paying a takeout price that was well over four times the biotech's value...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
01:37 , Jun 28, 2019 |  BC Innovations  |  Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
23:53 , Jun 18, 2019 |  BC Extra  |  Company News

BeiGene, SpringWorks form MapKure to develop BRAF inhibitor

Nine months after partnering to test a BRAF-MEK combination therapy, BeiGene and Pfizer spinout SpringWorks are collaborating again, this time forming a joint venture to develop a BeiGene BRAF inhibitor that could lead to combination...
22:15 , Jun 17, 2019 |  BC Extra  |  Company News

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

The most recent long-term data for bluebird bio's Zynteglo β thalassemia gene therapy show that about 80% of patients could hit payment milestones based on details the biotech disclosed about its outcomes-based pricing model on...
18:56 , Jun 17, 2019 |  BC Extra  |  Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
18:38 , Jun 2, 2019 |  BC Extra  |  Company News

Aslan’s change of course on eczema asset brings flexibility for future deals

Aslan's decision to restructure an existing deal with CSL for atopic dermatitis candidate ASLAN004, extending the partnership's scope to give the biotech full commercial rights, is part of Aslan's broader intention to gain flexibility for...